Obstetrics and Gynecology International [50] Ethics Committee of the American Society for Reproductive Medicine, “Fertility preservation and reproduction in cancer patients,” Fertility and Sterility, vol. 83, no. 6, pp. 1622–1628, 2005. [51] J. Donnez, P. Jadoul, J. Squiﬄet et al., “Ovarian tissue cryopreservation and transplantation in cancer patients,” Best Practice and Research, vol. 24, no. 1, pp. 87–100, 2010. [52] J. K. W. Yap and M. Davies, “Fertility preservation in female cancer survivors,” Journal of Obstetrics and Gynaecology, vol. 27, no. 4, pp. 390–400, 2007. [53] K. Oktay and O. Oktem, “Fertility preservation medicine: a new ﬁeld in the care of young cancer survivors,” Pediatric Blood and Cancer, vol. 53, no. 2, pp. 267–273, 2009. [54] T. Maltaris, H. Koelbl, R. Seufert et al., “Gonadal damage and options for fertility preservation in female and male cancer survivors,” Asian Journal of Andrology, vol. 8, no. 5, pp. 515– 533, 2006. [55] P. Jadoul, M. M. Dolmans, and J. Donnez, “Fertility preserva- tion in girls during childhood: is it feasible, eﬃcient and safe and to whom should it be proposed?” Human Reproduction Update, vol. 16, no. 6, Article ID dmq010, pp. 617–630, 2010. [56] G. D. Smith, P. C. Seraﬁni, J. Fioravanti et al., “Prospective randomized comparison of human oocyte cryopreservation with slow-rate freezing or vitriﬁcation,” Fertility and Sterility, vol. 94, no. 6, pp. 2088–2095, 2010. [57] L. Rienzi, S. Romano, L. Albricci et al., “Embryo development of fresh ‘versus’ vitriﬁed metaphase II oocytes after ICSI: a prospective randomized sibling-oocyte study,” Human Repro- duction, vol. 25, no. 1, pp. 66–73, 2010. [58] A. Revel, S. Revel-Vilk, E. Aizenman et al., “At what age can human oocytes be obtained?” Fertility and Sterility, vol. 92, no. 2, pp. 458–463, 2009. [59] C. J. Poirot, H. Martelli, C. Genestie et al., “Feasibility of ovarian tissue cryopreservation for prepubertal females with cancer,” Pediatric Blood and Cancer, vol. 49, no. 1, pp. 74–78, 2007. [60] P. Morice, D. Castaigne, C. Haie-Meder et al., “Laparoscopic ovarian transposition for pelvic malignancies: indications and functional outcomes,” Fertility and Sterility, vol. 70, no. 5, pp. 956–960, 1998. [61] Z. Blumenfeld, I. Avivi, S. Linn, R. Epelbaum, M. Ben-Shahar, and N. Haim, “Prevention of irreversible chemotherapy- induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy,” Human Reproduction, vol. 11, no. 8, pp. 1620– 1626, 1996. [62] Z. Blumenfeld, “Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxi- city and premature ovarian failure: the role of inhibin-A and -B as markers,” Molecular and Cellular Endocrinology, vol. 187, no. 1-2, pp. 93–105, 2002. [63] B. Pereyra Pacheco, J. M. Mendez Ribas, G. Milone et al., “Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report,” Gynecologic Oncology, vol. 81, no. 3, pp. 391–397, 2001. [64] Z. Blumenfeld and M. Von Wolﬀ, “GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy,” Human Reproduction Update, vol. 14, no. 6, pp. 543–552, 2008. [65] R. Ismail-Khan, S. Minton, C. Cox et al., “Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer. A randomized trial using the 7 GnRH agonist (triptorelin) during chemotherapy,” Journal of Clinical Oncology, vol. 26, 2008, 12 (abstr 524). [66] H. O. Critchley and W. H. Wallace, “Impact of cancer treatment on uterine function,” Journal of the National Cancer Institute, no. 34, pp. 64–68, 2005. [67] H. O. D. Critchley, W. H. B. Wallace, S. M. Shalet, H. Mamtora, J. Higginson, and D. C. Anderson, “Abdominal irradiation in childhood; the potential for pregnancy,” British Journal of Obstetrics and Gynaecology, vol. 99, no. 5, pp. 392–394, 1992. [68] H. Sudour, P. Chastagner, L. Claude et al., “Fertility and pregnancy outcome after abdominal irradiation that included or excluded the pelvis in childhood tumor survivors,” Interna- tional Journal of Radiation Oncology Biology Physics, vol. 76, no. 3, pp. 867–873, 2010. [69] H. Critchley, “Factors of importance for implantation and problems after treatment for childhood cancer,” Medical and Pediatric Oncology, vol. 33, no. 1, pp. 9–14, 1999. [70] E. Larsen, K. Schmiegelow, C. Rechnitzer et al., “Radiotherapy at a young age reduces uterine volume of childhood cancer survivors,” Acta Obstetricia et Gynecologica Scandinavica, vol. 83, no. 1, pp. 96–102, 2004. [71] L. B. Signorello, S. S. Cohen, C. Bosetti et al., “Female survivors of childhood cancer: preterm birth and low birth weight among their children,” Journal of the National Cancer Institute, vol. 98, no. 20, pp. 1453–1461, 2006. [72] A. M. Chiarelli, L. D. Marrett, and G. A. Darlington, “Pregnancy outcomes in females after treatment for childhood cancer,” Epidemiology, vol. 11, no. 2, pp. 161–166, 2000. [73] M. M. Hawkins and R. A. Smith, “Pregnancy outcomes in childhood cancer survivors: probable eﬀects of abdominal irradiation,” International Journal of Cancer, vol. 43, no. 3, pp. 399–402, 1989. [74] S. Lie Fong, M. M. van den Heuvel-Eibrink, M. J. C. Eijkemans, I. Schipper, C. W. P. M. Hukkelhoven, and J. S. E. Laven, “Pregnancy outcome in female childhood cancer survivors,” Human Reproduction, vol. 25, no. 5, pp. 1206–1212, 2010. [75] L. B. Signorello, J. J. Mulvihill, D. M. Green et al., “Stillbirth and neonatal death in relation to radiation exposure before conception: a retrospective cohort study,” The Lancet, vol. 376, no. 9741, pp. 624–630, 2010.